Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 15161916
Sekiya F, Poulin B, Kim YJ, Rhee SG (2004) Mechanism of tyrosine phosphorylation and activation of phospholipase C-gamma 1. Tyrosine 783 phosphorylation is not sufficient for lipase activation. J Biol Chem 279, 32181-90 15161916
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

Y771-p - PLCG1 (rat)
Modsite: IGTAEPDyGALyEGR SwissProt Entrez-Gene
Orthologous residues
PLCG1 (human): Y771‑p, PLCG1 iso2 (human): Y771‑p, PLCG1 (mouse): Y771‑p, PLCG1 (rat): Y771‑p, PLCG1 (cow): Y771‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody
Relevant cell lines - cell types - tissues:  3T3 (fibroblast) [SHP-2 (mouse), homozygous knockout], Null-TV1
Cellular systems studied:  cell lines
Species studied:  human, mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
vanadate, PDGF increase

Y783-p - PLCG1 (rat)
Modsite: EGRNPGFyVEANPMP SwissProt Entrez-Gene
Orthologous residues
PLCG1 (human): Y783‑p, PLCG1 iso2 (human): Y783‑p, PLCG1 (mouse): Y783‑p, PLCG1 (rat): Y783‑p, PLCG1 (cow): Y783‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody
Relevant cell lines - cell types - tissues:  3T3 (fibroblast) [SHP-2 (mouse), homozygous knockout], A431 (epithelial), Jurkat (T lymphocyte), Null-TV1 [PLCG1 (rat)], RAMOS (B lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Enzymes shown to modify site in vitro
Type Enzyme
KINASE Src (human)
KINASE EGFR (human)
KINASE ZAP70 (human)
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
vanadate, PDGF increase

Y1253-p - PLCG1 (rat)
Modsite: EGsFEARyQQPFEDF SwissProt Entrez-Gene
Orthologous residues
PLCG1 (human): Y1253‑p, PLCG1 iso2 (human): Y1254‑p, PLCG1 (mouse): Y1253‑p, PLCG1 (rat): Y1253‑p, PLCG1 (cow): Y1254‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody
Relevant cell lines - cell types - tissues:  3T3 (fibroblast) [SHP-2 (mouse), homozygous knockout], A431 (epithelial), Jurkat (T lymphocyte), Null-TV1 [PLCG1 (rat)], RAMOS (B lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human, mouse
Enzymes shown to modify site in vitro
Type Enzyme
KINASE EGFR (human)
KINASE Src (human)
KINASE ZAP70 (human)
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PDGF increase